


CLAIMS

1. Compounds of the general formula (I):



5 in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- Alk-C(=O)-(O)_m-Ar,
- 10 - Alk-C(=O)-(O)_m-Het,
- Alk-C(=O)-(O)_m-Alk,
- Alk-C(=O)-(O)_m-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-(O)_m-Ar,
- 15 - Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

20

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and -NO₂;

in which, in the definitions of R1-R6:

25 each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and -NO₂;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH,

-CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_m-Alk, -NRR', -Het, -NO₂, -S(O)_nAr and -S(O)_nAlk;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

- 5 and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts,

with the exception of the compounds for which:

1) R₁ = -CH₂-C(=O)Me, R₂ = -Me, X = O, R₃, R₅ = H and each R₄, R₆ = H or OMe.

10

2. Compounds of the formula (I) according to Claim 1, in which:

X = O or S;

R₁ is chosen from:

- Alk-COOH,
- 15 - Alk-C(=O)-(O)_m-Ar,
- Alk-C(=O)-(O)_m-Het,
- Alk-C(=O)-(O)_m-Alk,
- Alk-C(=O)-(O)_m-cycloalkyl,
- Alk-C(=O)NRR',
- 20 - Alk-(O)_m-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R₂ represents -Ar or -cycloalkyl;

25

R₃, R₄, R₅ and R₆, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and -NO₂;

in which, in the definitions of R₁-R₆:

- each of the Alk, which may be identical or different, is optionally and independently
- 30 substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and -NO₂;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_m-Alk, -NRR', -Het, -NO₂, -S(O)_nAr and -S(O)_nAlk;

5 R and R' are chosen independently from H and Alk;

m = 0 or 1,

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

10 3. Compounds of the formula (I) according to Claim 1, in which:

X = S;

R1 is chosen from:

- Alk-COOH,

- Alk-C(=O)-(O)_m-Ar,

15 - Alk-C(=O)-(O)_m-Het,

- Alk-C(=O)-(O)_m-Alk,

- Alk-C(=O)-(O)_m-cycloalkyl,

- Alk-C(=O)NRR',

- Alk-(O)_m-Ar,

20 - Alk-O-Alk,

- Alk-O-Alk-Ar,

- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

25 R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and -NO₂;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and -NO₂;

30

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH,

-CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_m-Alk, -NRR', -Het, -NO₂, -S(O)_nAr and -S(O)_nAlk;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

- 5 and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

4. Compounds of the formula (I) according to any one of the preceding claims, in which R₃, R₄, R₅, R₆ = H.

10

5. Compounds of the formula (I) according to any one of the preceding claims, in which X = S.

6. Compounds of the formula (I) according to any one of the preceding claims, in which R₂ = Ar optionally substituted by -CN or -COOH, or alkyl optionally substituted by -COOH.

15

7. Compounds of the formula (I) according to any one of the preceding claims, in which R₂ = phenyl optionally substituted by -CN or -COOH.

20

8. Compounds of the formula (I) according to any one of the preceding claims, in which R₂ = phenyl substituted by -CN.

9. Compounds of the formula (I) according to any one of the preceding claims, in which m = 0.

25

10. Compounds of the formula (I) according to any one of the preceding claims, in which R₁ = -CH₂-COOH, -CH₂-C(=O)-(O)_m-Ar, -CH₂-C(=O)-(O)_m-Het, -CH₂-C(=O)-(O)_m-Alk, -CH₂-C(=O)NRR', -CH₂-(O)_m-Ar, -CH₂-O-Alk, -CH₂-O-Alk-Ar or -CH₂-O-Het, in which

30

Ar is optionally substituted by one or more groups chosen from Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-(O)_m-Alk, -Alk-C(=O)-(O)_mAlk, -S(O)_n-Ar, -S(O)_n-Alk, -O-CF₃, -CN and -OH,

in which $m = 0$ or 1 , $n = 2$.

11. Compounds of the formula (I) according to any one of the preceding claims, in which $R1 = -CH_2-C(=O)-Ar$, $-CH_2-C(=O)-Alk$ or $-(CH_2)_{m'}-(O)_m-Ar$, in which

5 Ar is optionally substituted by one or more groups chosen from Hal, $-OAlk$, $-Ar$, $-Alk$, $O-Alk-Ar$, $-C(=O)-(O)_m-Alk$, $-Alk-C(=O)-(O)_mAlk$, $-S(O)_n-Ar$, $-S(O)_n-Alk$, $-O-CF_3$, $-CN$ and $-OH$,

in which $m = 0$ or 1 , $m' = 1$ or 2 , $n = 2$.

10 12. Compounds of the formula (I) according to any one of the preceding claims, in which $m' = 2$ if $m = 1$.

13. Compounds of the formula (I) according to any one of the preceding claims, in which $R1 = -CH_2-C(=O)-Alk$.

15

14. Compounds of the formula (I) according to Claim 13, in which $Alk = -CMe_3$.

15. Compounds of the formula (I) according to any one of the preceding claims, in which $Ar = \text{phenyl}$.

20

16. Compounds of the formula (I) according to any one of the preceding claims, in which $R1 = -CH_2-C(=O)-\text{phenyl}$ or $-CH_2-\text{phenyl}$ in which phenyl is optionally substituted by one or more groups chosen from $-Hal$, $-OAlk$, $-CN$, $-SO_2-Alk$ and $-Alk$.

25 17. Compounds of the formula (I) according to any one of the preceding claims, chosen from:

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-chlorophenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-methoxyphenyl)ethanone;

30 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-biphenyl-4-ylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-*p*-tolylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-methoxyphenyl)ethanone;


2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-fluorophenyl)ethanone;

- 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3-methoxyphenyl)ethanone;
 methyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3-methoxypropionate;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;
 5 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylpropan-1-one;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;
 1-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3,3-dimethylbutan-2-one;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-naphthalen-2-ylethanone;
 10 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,3-dichloro-4-methoxyphenyl)ethanone;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxy-3-methoxyphenyl)ethanone;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxy-5-fluorophenyl)ethanone;
 (3-hydroxybenzo[*b*]thiophen-2-yl)phenylmethanone;
 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)acetamide;
 15 {3-[2-(4-fluorophenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;
 (3-phenethyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;
 methyl 3-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethoxy]phenyl}propionate;
 {3-[2-(naphthalen-1-yloxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;
 {3-[2-(2-methoxyphenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;
 20 1-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethyl]phenyl}ethanone;
 ethyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-4-phenylbutyrate;
 [3-(3-phenoxypropoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 [3-(4-*tert*-butylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 [3-(2-benzenesulfonylmethylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 25 methyl 4-(2-benzoylbenzo[*b*]thiophen-3-yloxymethyl)benzoate;
 phenyl[3-(4-trifluoromethoxybenzyloxy)benzo[*b*]thiophen-2-yl]methanone;
 [3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 [3-(4-methylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 (3-benzyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;
 30 [3-(2,3-difluorobenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;
 sodium 2-(4-cyanobenzoyl)benzo[*b*]thiophen-3-olate;
 4-[3-(2-chloro-4-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(3,4-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

- 4-[3-(3-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(3-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(4-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 5 4-[3-(3,5-bis-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 methyl 4-[2-(4-cyanobenzoyl)benzo[*b*]thiophen-3-yloxymethyl]benzoate;
 4-[3-(4-fluoro-2-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-(3-pentafluorophenylmethoxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;
 4-[3-(2,6-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 10 4-[3-(4-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(4-bromo-2-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2-methylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 15 4-[3-(2,6-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(3-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(4-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-(3-benzyloxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;
 20 4-[3-(3-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(3,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(3,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 25 4-[3-(2,3-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(4-methanesulfonylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(4-iodobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-{3-[2-(4-chlorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 4-[3-(2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 30 4-{3-[2-(2-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 4-[3-(2-biphenyl-4-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-[3-(2-oxo-2-*p*-tolylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-{3-[2-(4-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

- 4-[3-(2-adamantan-1-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-{3-[2-(4-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 4-{3-[2-(3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 4-{3-[2-(2-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 5 4-{3-[2-(4-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;
 4-{3-[2-(3,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzo-
 nitrile;
 4-{3-[2-(2,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzo-
 nitrile;
 10 4-[3-(2-naphthalen-2-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;
 4-{3-[2-(4-benzyloxy-3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}-
 benzonitrile;
 4-{3-[2-(2-benzyloxy-5-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}-
 benzonitrile;
 15 (3-hydroxybenzofuran-2-yl)phenylmethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(4-chlorophenyl)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(2-methoxyphenyl)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-biphenyl-4-ylethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-*p*-tolylethanone;
 20 2-(2-benzoylbenzofuran-3-yloxy)-1-(4-methoxyphenyl)ethanone;
 1-adamantan-1-yl-2-(2-benzoylbenzofuran-3-yloxy)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(4-fluorophenyl)ethanone;
 methyl 2-(2-benzoylbenzofuran-3-yloxy)-3-methoxypropionate;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;
 25 2-(2-benzoylbenzofuran-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;
 2-(2-benzoylbenzofuran-3-yloxy)-1-naphthalen-2-ylethanone;
 and also the stereoisomers thereof, the racemates thereof and the pharmaceutically
 30 acceptable salts.

18. Process for the preparation of the compounds of the formula (I) according to any one of the preceding claims, comprising the step consisting in using the compound of the formula (IV):




5 on a halo derivative (V):



in which, in formulae (IV) and (V), X and R1-R6 are as defined in any one of the preceding claims, in equimolar amount, in a polar solvent, at a temperature of between -20 and 200°C.


10

19. Process according to Claim 18, for which the said compound of the formula (IV) is prepared by addition of the corresponding derivative of the formula (II):



in which R3-R6 and X are as defined in any one of Claims 1 to 16, and R represents a hydrogen atom or an alkyl radical, to a 2-haloethanone derivative of the formula (III):


15



in which Hal represents a halogen atom, and R₂ is as defined in any one of Claims 1 to 16, in a polar solvent, at a temperature of from -20 to 200°C, followed by cyclization in a polar solvent at a temperature of from -20 to 200°C.

- 5 20. Process for the preparation of the compounds of the formula (I) according to Claim 18 or 19, for which the said polar solvent is chosen from: ethanol, methanol, water, DMF, NMP, DMSO, iPrOH.

21. . Pharmaceutical compositions comprising a compound of the formula (I):



in which:

X = O or S;

R₁ is chosen from:

- Alk-COOH,
- 15 - Alk-C(=O)-(O)_m-Ar,
- Alk-C(=O)-(O)_m-Het,
- Alk-C(=O)-(O)_m-Alk,
- Alk-C(=O)-(O)_m-cycloalkyl,
- Alk-C(=O)NRR',
- 20 - Alk-(O)_m-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

25 R₂ is chosen from -Alk, -Ar and -cycloalkyl;

R₃, R₄, R₅ and R₆, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and -NO₂;

in which, in the definitions of R₁-R₆:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and -NO₂;

- 5 each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_m-Alk, -NRR', -Het, -NO₂, -S(O)_nAr and -S(O)_nAlk;


R and R' are chosen independently from H and Alk;

- 10 m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

22. Composition according to Claim 21, in which, in the compound of the formula
15 (I), X and R₁-R₆ are as defined according to any one of Claims 1 to 17.

23. Use of a compound of the formula (I):



in which:

- 20 X = O or S;

R₁ is chosen from:

- Alk-COOH,
- Alk-C(=O)-(O)_m-Ar,
- Alk-C(=O)-(O)_m-Het,
- 25 - Alk-C(=O)-(O)_m-Alk,
- Alk-C(=O)-(O)_m-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-(O)_m-Ar,

- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

5 R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and -NO₂;

in which, in the definitions of R1-R6:

10 each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and -NO₂;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, 15 -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_m-Alk, -NRR', -Het, -NO₂, -S(O)_nAr and -S(O)_nAlk;

R and R' are chosen independently from H and Alk;

m = 0 or 1,

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically 20 acceptable salts.

for the preparation of a medicament for reducing hyperglycaemia.

24. Use of a compound of the formula (I) according to Claim 23, for which the said 25 medicament is for the treatment of diabetes.

25. Use of a compound of the formula (I) according to Claim 23 or 24, for which the said medicament is for the treatment of non-insulin-dependent diabetes.

30 26. Use of a compound of the formula (I) according to any one of Claims 23, 24 and 25, for which the said medicament is for the treatment of dyslipidaemia and/or obesity.

27. Use according to any one of Claims 23 to 26, for which the said medicament is for the treatment of diabetes-related microvascular and macrovascular complications.
- 5 28. Use of a compound of the formula (I) according to Claim 27, for which the microvascular and macrovascular complications are chosen from atherosclerosis, arterial hypertension, inflammatory processes, macroangiopathy, microangiopathy, retinopathy and neuropathy.
- 10 29. Use of a compound of the formula (I) according to any one of Claims 23 to 28, for which, in the compound of the formula (I), X and R1-R6 are as defined according to any one of Claims 1 to 17.